All In Biotech

Drug Trial Radar · NCT02047734

Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis

A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients

Last checked: Nov 20, 2026Latest source record: Feb 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,320 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,320

Actual

Start

Dec 3, 2013

Primary completion

Mar 27, 2017

Study completion Apr 13, 2017

Sponsor

Lead sponsor
CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Jan 28, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a two-part trial consisting of Part A (see NCT01628393) and Part B, presented within this record. The primary objective of Part B is to assess whether the clinical efficacy of ozanimod (RPC1063) is superior to interferon beta-1a (IFN β-1a; Avonex®) in reducing the rate of clinical relapses at the end of Month 24 in patients with relapsing multiple sclerosis (RMS).

Conditions

  • Relapsing Multiple Sclerosis

Interventions

  • OzanimodDrug

    Oral capsule, daily for 24 months

  • Ozanimod placeboDrug

    Oral capsule, daily for 24 months

  • Interferon beta-1aDrug

    Intramuscular injection, 30 µg, weekly for 24 months

  • Interferon beta-1a placeboDrug

    Intramuscular injection, weekly for 24 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adjusted Annualized Relapse Rate (ARR) at the End of Month 24Time frame: At the end of month 24

Locations

299 sites in 21 countries. Site status is shown where the registry gives one.

  • Receptos Study Site 115

    Phoenix, Arizona

  • Xenoscience

    Phoenix, Arizona

  • Receptos Study Site 118

    Phoenix, Arizona

  • Saint Josephs Hosptial and Medical Center

    Phoenix, Arizona

  • Territory Neurology and Research Institute

    Tucson, Arizona

  • Receptos Study Site 119

    Tucson, Arizona

  • Alta Bates Summit Medical Center

    Berkeley, California

  • Receptos Study Site 110

    Berkeley, California

  • Receptos Study Site 122

    Long Beach, California

  • Receptos Study Site 112

    Sacramento, California

  • University of California Davis Medical Center

    Sacramento, California

  • Multiple Sclerosis Center at UCSF

    San Francisco, California

  • Receptos Study Site 120

    San Francisco, California

  • Denver Neurological Research LLC

    Denver, Colorado

  • Receptos Study Site 127

    Denver, Colorado

  • Neurology Associates PA

    Maitland, Florida

  • Receptos Study Site 114

    Maitland, Florida

  • Receptos Study Site 124

    Pompano Beach, Florida

  • Neurostudies Inc

    Port Charlotte, Florida

  • Receptos Study Site 123

    Port Charlotte, Florida

  • Infinity Clinical Research LLC

    Sunrise, Florida

  • West Georgia Sleep Disorder Center and Neurology Associates

    Douglasville, Georgia

  • Consultants In Neurology

    Northbrook, Illinois

  • Receptos Study Site 113

    Northbrook, Illinois

  • Receptos Study Site 121

    St Louis, Missouri

  • Washington University

    St Louis, Missouri

  • Receptos Study Site 101

    Charlotte, North Carolina

  • The Neurological Institute PA

    Charlotte, North Carolina

  • Neurology and Neuroscience Associates Inc.

    Akron, Ohio

  • Receptos Study Site 107

    Akron, Ohio

  • Receptos Study Site 104

    Cleveland, Ohio

  • Receptos Study Site 109

    Philadelphia, Pennsylvania

  • Receptos Study Site 102

    Seattle, Washington

  • The Polyclinic

    Seattle, Washington

  • Receptos Study Site 125

    Tacoma, Washington

  • Grodno Clinical Regional Hospital

    Grodno, Belarus

  • Receptos Study Site 907

    Grodno, Belarus

  • Gomel Regional Clinical Hospital

    Homyel, Belarus

  • Receptos Study Site 904

    Homyel, Belarus

  • Minsk Municipal Clinical Hospital 5

    Minsk, Belarus

Showing 40 of 299 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.